Akinnawo Christianah Aarinola, Dube Admire
School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa.
Adv Ther (Weinh). 2025 Apr;8(4). doi: 10.1002/adtp.202400189. Epub 2024 Aug 20.
Globally we are faced with a significant burden of tuberculosis (TB), which is difficult to eradicate due to patients' non-adherance, and drug-resistant strains that are spreading at an alarming rate. Novel approaches are required to improve diagnosis and treatment. Metallic nanoparticles (MNPs) have demonstrated potential as sensor probes and in combination therapy, which combines MNPs with antimycobacterial drugs to develop new treatment and theranostic approaches. To strengthen the theoretical foundation towards the clinical application of TB nanomedicine, this review focuses on the properties and effectiveness of therapeutically relevant MNPs. We also elaborate on their antimycobacterial mechanisms. This review aims to analyze the body of literature on the topic, pinpoint important empirical findings, and identify knowledge gaps that could provide a basis for future research endeavors and translation of the technologies. Current data suggest that MNPs are potential systems for efficient diagnosis and treatment although additional pre-clinical and clinical research is needed to bring these technologies to the clinic.
在全球范围内,我们面临着严重的结核病负担,由于患者的不依从性以及耐药菌株以惊人的速度传播,结核病难以根除。需要新的方法来改善诊断和治疗。金属纳米颗粒(MNPs)已显示出作为传感器探针以及在联合治疗中的潜力,联合治疗是将MNPs与抗分枝杆菌药物相结合以开发新的治疗和诊疗方法。为了加强结核病纳米医学临床应用的理论基础,本综述重点关注治疗相关MNPs的特性和有效性。我们还详细阐述了它们的抗分枝杆菌机制。本综述旨在分析该主题的文献主体,找出重要的实证研究结果,并识别知识空白,这些可为未来的研究工作和技术转化提供基础。目前的数据表明,MNPs是高效诊断和治疗的潜在系统,尽管需要更多的临床前和临床研究才能将这些技术应用于临床。